<DOC>
	<DOCNO>NCT02947022</DOCNO>
	<brief_summary>Purpose : There two goal prospective single arm study ; see increase amount gadolinium 24 hour urine collection follow infusion treatment Calcium Zinc DTPA , see reduction elimination gadolinium deposition disease ( GDD ) symptom . Participants : Twenty ( 20 ) patient suffer gadolinium deposition disease ( GDD ) Procedures : Over series three ( 3 ) treatment time-points patient treat IV Ca-DTPA day one , Zn-DTPA day two .</brief_summary>
	<brief_title>Effects IV-Administered Ca-DTPA Zn-DTPA To Treat Patients With Gadolinium Deposition Disease</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Hyperpigmentation</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>Exhibiting 3 great follow symptom must present administered GBCA : Cognitive disturbance Extremity pain Headache Chest wall pain Skin induration Skin hyperpigmentation Skin pain Arthralgia Pregnant lactate Less 18 year old No evidence gadolinium ( show previous demonstration Gd urine analysis bone biopsy ) Known connective tissue disease Systemic Lupus Erythematosus Scleroderma Severe hemochromatosis Wilson 's disease Glomerular Filtration Rate ( GFR ) â‰¤ 60 Have investigational drug within last 30 day Unable give write consent Multiple Sclerosis Chronic heart failure Cirrhosis liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>gadolinium</keyword>
	<keyword>deposition</keyword>
	<keyword>GBCA</keyword>
	<keyword>Extremity Pain</keyword>
	<keyword>Skin Pain</keyword>
	<keyword>Chest Wall Pain</keyword>
</DOC>